Skip to content

Study to Test Sensitivity and Specificity of Passive Wave Pressure Device in Determining Ischemic Stroke

A NonRandomized, Multicenter, NonSig Risk Study With a NonInv, Passive PressureWave Method of Diagnosing Cerebral Anomalies to Develop a Diag. Algorithm for Cerebral Isch and to Test Sens./Spec. of This Algorithm in Determining Isch Stroke

Status
Terminated
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01643525
Enrollment
29
Registered
2012-07-18
Start date
2012-06-30
Completion date
2012-12-31
Last updated
2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic Stroke

Keywords

Ischemic Stroke

Brief summary

That the Jan Medical Nautilus NeuroWaveTM system provides significantly higher sensitivity to hyper acute ischemic stroke than does CT.

Detailed description

In spite of the fact that approximately 800,000 strokes are diagnosed in the United States each year, many physicians and patients have approached the management of stroke with a sense of futility. However, within the past 2 decades, following the advent of computerized tomography (CT), medical interest has turned toward stroke and effective interventions to treat and prevent it have received attention. CT and/or magnetic resonance imaging (MRI) are the typical diagnostic tools used in the event of a stroke alert. These studies are done on an emergent or urgent basis, since, to be effective, treatments for ischemic and hemorrhagic stroke must be delivered soon after onset of the illness. In an effort to institute an appropriate therapeutic regime, laboratory and structural diagnostic studies are required to be done as rapidly as possible to determine pathological etiology, size, and location of concern. The speed at which a diagnosis is made and a treatment plan established often determines patient outcome and any associated complications. This is especially true when evaluating patients for ischemic stroke where there is a narrow 3 hour window of opportunity in which to resolve the clot with IV .before permanent neurological impairment results, and up to 8 additional hours with the use if intra arterial (IA) t-PA or interventional mechanical embolectomy procedures are utilized. Current treatment modalities include pharmacologic thrombolytic drugs utilized to disrupt or dissolve clots located in the distal vasculature or mechanical intervention in larger vessels. Since many patients do not recognize the symptoms of stroke they do not seek medical attention immediately. Significant time is then often lost from the onset of the stroke before seeking medical help / treatment. Although the current technologies are quite adequate as diagnostic tools for hemorrhagic stroke and for identifying subdural hematomas, and other pooled blood abnormalities which would preclude t-PA therapy, they are largely ineffective at positively identifying stroke during the limited therapeutic window of time. Positive identification of ischemia itself is rarely possible or practical with CT or within the limited therapeutic window. As such the diagnostic determination and associated treatment decisions are based on the unsatisfactory basis of exclusion.

Interventions

Non-invasive device designed to detect pressure signals from the skull to aid in the diagnosis of ischemic stroke.

Sponsors

Jan Medical, Inc.
Lead SponsorINDUSTRY

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
Yes

Inclusion criteria

* Symptoms consistent with stroke with known onset \< 12 hours prior to enrollment and planned recording with the Nautilus NeuroWave System * Suspected pathology of following vessels: internal carotid artery, ACA, MCA, PCA, basilar or other anterior or posterior cerebral vessels or normal anatomy * Subject is planned to undergo standard stroke triage imaging protocol * Able to understand and provide signed informed consent, or have a Legally Authorized Representative willing to provide informed consent on subject's behalf

Exclusion criteria

* Known to meet hospital criteria for brain death * Not a candidate for CT, MRI * unknown time of stroke symptom onset. * Psychologically unstable and not able to cooperate * Not suitable for participation in this study in the opinion of the Investigator

Design outcomes

Primary

MeasureTime frameDescription
Number of Participants With Device Related Adverse Events2-3 days, at subject exit (variation of subject exit date depended on when subject obtained their radiology imaging to confirm ischemic stroke)Count the number of participants with device related adverse events

Countries

United States

Participant flow

Participants by arm

ArmCount
Nautilus NeuroWave Recording Arm
Nautilus NeuroWaveTM System Nautilus NeuroWaveTM System: Non-invasive device designed to detect pressure signals from the skull to aid in the diagnosis of ischemic stroke.
29
Total29

Baseline characteristics

CharacteristicNautilus NeuroWave Recording Arm
Age, Continuous55.3 years
STANDARD_DEVIATION 16.2
Region of Enrollment
United States
29 participants
Sex/Gender, Customized
Females Known
16 participants
Sex/Gender, Customized
Gender Unknown
6 participants
Sex/Gender, Customized
Males Known
7 participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
0 / 29
serious
Total, serious adverse events
0 / 29

Outcome results

Primary

Number of Participants With Device Related Adverse Events

Count the number of participants with device related adverse events

Time frame: 2-3 days, at subject exit (variation of subject exit date depended on when subject obtained their radiology imaging to confirm ischemic stroke)

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Nautilus NeuroWave Recording ArmNumber of Participants With Device Related Adverse Events0 Participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026